Longevity

Epitalon

Synthetic tetrapeptide

Lab studiesTelomeres and cell aging1 2

Community reportsSleep · body-clock routines4 7

No FDA-approved Epitalon product.

What does it do?

Synthetic pineal-derived tetrapeptide studied in cellular aging, circadian and immune models. Human longevity benefit is unestablished.

Approved & studied uses

Telomere biology research

1 2

Cell studies investigate telomerase and telomere maintenance; these are not human lifespan results.

Community uses Reported, unvalidated

Cellular aging

Telomeres, mitochondria and lifespan hypotheses; animal longevity findings do not prove human rejuvenation.

Brain, sleep and retina

Source discusses pineal function, neurogenesis and retinal studies.

Immune aging

Thymus/T-cell and surveillance claims need clinical confirmation.

Reasons people report using it; these do not establish benefit.22

Evidence limits

View research →

Whether synthetic Epitalon improves any meaningful human aging outcome.1

6 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

Long-term cancer uncertainty

FDA raises a mechanistic concern about persistent telomerase activation; this is not proof that Epitalon causes cancer in humans.6

No FDA-approved Epitalon product.

Molecular information

5 6

Amino-acid sequence

4 residues · N → C5 6

Length4 amino acids

Molecular weight · Da390.35 Da

Formula, sequence notation & identity

Molecular formulaC₁₄H₂₂N₄O₉5 6

A–E–D–G

H-Ala-Glu-Asp-Gly-OH (AEDG)

Synthetic Epitalon / Epithalon is distinct from epithalamin, a pineal extract. Extract studies cannot silently stand in for this molecule.

Pep-Pedia identity details

4 amino acids · 390.35 Da

Ala-Glu-Asp-Gly

Reference description; checked chemical identity above takes precedence when available.22

Pharmacokinetics

How long does it stay in the body?

Reported half-lifeHuman half-life not established6

FDA’s assessment found no pharmacokinetic data for Epitalon free base or acetate. No quantitative human elimination curve is justified.

No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.

What to expect

Study outcomes

Cellular effects do not establish longevity

Telomerase activity and telomere changes were reported in cell cultures. No human survival improvement was measured.1 2

Melatonin is a surrogate

The cited report concerns melatonin rhythms; it does not establish insomnia treatment or longer human lifespan.4

Reported timelines

Reference & community

Injection: days 3–7; nasal: week 1

Reported sleep changes.22

Weeks 2–4

Reported energy/skin changes.22

Oral: weeks 3–4 to months 2–3

Slower claimed changes; no validated timeline.22

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Topic

Primary goal

Anti-aging48%

General wellness18%

Cognitive enhancement12%

Recovery/Healing9%

Other: Sleep5%

The source hides 11 additional categories. Their labels and percentages are unavailable.

Number of responses to this question: not disclosed.

Source & limitations

The source displays “1540 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
This is a dated snapshot, not a live survey or current recommendation.

Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

Source corrections

Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations.

Source interaction labels and timelines are claims, not combination-safety evidence.

Route

Scroll to compare all columns →

One row for each documented route and dose or dose range
Route	Dose	Frequency	Goal / evidence	Duration	References
SubQ	200-500μg	Daily	Evidence-Based Protocol (Recommended)Reference report	10-20 days per cycle	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Injectable
SubQ	100μgStarting dose	Daily	Conservative StartReference report	10-20 days per cycle	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Injectable
SubQ	300μg	Daily	Russian Clinical EquivalentReference report	10-20 days per cycle	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Injectable
SubQ	5-10 mg	Daily	Traditional Western (Anecdotal)Reference report	10-20 days per cycle	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Injectable
SubQ	50μg	Daily	Ultra-Low DoseReference report	10-20 days per cycle	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Injectable
OralOral capsule	2-3 mg	Twice daily	Corrected Oral ProtocolReference report	20-30 days	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Oral
OtherSublingual	1 mg	Twice daily	Conservative OralReference report	20-30 days	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Oral
Oral	10-15 mg	Daily	Traditional (Possibly Excessive)Reference report	20-30 days	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Oral
IntranasalNasal spray	1 mg	Twice daily	Evidence-Based NasalReference report	10-20 days	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Nasal
IntranasalNasal spray	500μg	Once daily	Conservative NasalReference report	10-20 days	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Nasal
IntranasalNasal spray	5 mg	Twice daily	Traditional (Likely Excessive)Reference report	10-20 days	22
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations. Source interaction labels and timelines are claims, not combination-safety evidence. Source tabs Nasal

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports22

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period: 10-20 days per cycle
Break: 4-6 months between cycles

Reported timing

Morning injection preferred to align with natural circadian rhythms

Oral

Use period: 20-30 days
Break: 3-4 months between cycles

Reported timing

Morning dose 30 minutes before breakfast

Nasal

Use period: 10-20 days
Break: 4-6 months

Reported timing

Morning for energy, evening for sleep enhancement

Animal and cell protocols 1

Laboratory exposures cannot establish a human dose.

Scroll to compare all columns →

Animal and cell exposures
Route	Dose	Frequency	Goal / evidence	Duration	References
CellsIn vitro	50 ng/mL	Culture exposure	Telomerase and telomere measurementsCells	Four days	1 6
Population Cultured human fetal lung fibroblasts Context Cell concentration is not a human dose.

Side effects & safety

Long-term cancer uncertainty

FDA raises a mechanistic concern about persistent telomerase activation; this is not proof that Epitalon causes cancer in humans.

Immune and impurity concerns

FDA flags aggregation and immunogenicity concerns.

Sparse human safety

Missing clinical and pharmacokinetic data prevent reliable estimates of delayed or uncommon harms.

Identity mismatch

Pineal-extract findings cannot establish the synthetic tetrapeptide’s safety.

Additional reported cautions

Reference reports22

Cancer context

Telomerase effects warrant specialist review with malignancy or cancer therapy.

Injection and allergy

Inflammation, allergy, vivid dreams; evaluate new/changing moles, unusual fatigue or weakness.

Oral/nasal routes

Variable absorption; digestive upset or nasal irritation, bleeding, infection, sinus pressure.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

9 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Cortexin

Caution reported

Overlapping neurological claims.22

Reference report · Pep-Pedia label: Monitor Combination

Melatonin

Unverified pairing

Proposed circadian complement.22

Reference report · Pep-Pedia label: Synergistic

Thymalin

Unverified pairing

Historical immune-aging pairing.22

Reference report · Pep-Pedia label: Synergistic

NAD+ precursors

Unverified pairing

Untested pathway complement.22

Reference report · Pep-Pedia label: Compatible

Growth hormone peptides

Unverified pairing

Untested pairing.22

Reference report · Pep-Pedia label: Compatible

BPC-157

Unverified pairing

Safety not established.22

Reference report · Pep-Pedia label: Compatible

Semax/Selank

Unverified pairing

Untested pairing.22

Reference report · Pep-Pedia label: Compatible

Cancer therapeutics

Unverified pairing

Oncology review needed.22

Reference report · Evidence context: Unknown

Other peptides, sleep medicines or cancer therapies

Not established

The cited assessment does not establish a human interaction profile. Absent reports are not evidence of compatibility.6

Research context

Reconstitution calculator

Enter your peptide amount and container size. Get a volume and a simple measurement scale.

1How much peptide do you have?

Total labeled amount of Epitalon.

2How much can your container hold?

Usable capacity of the destination vial or pen cartridge.

Measure with

1 dial unit = 0.01 mL on the documented V2 model. Confirm your pen’s scale.

Vial examples & blend contents Epitalon

Peptide reference

Listed amounts are packaging examples. Check your actual label.

Suggested final volume mL

Estimated water to add≈ mL

For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.

1 pen unit (one dial step)=

Measurement scale Conversions, not recommended doses
Pen units	Amount	Volume

Other simple scales

Convert a specific amount

Enter an amount to calculate its volume and device setting.

Amount to measure

Measuring-tool capacity

Calculation & assumptions

The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.

The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.

V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗

Reconstitution

No validated clinical preparation

The reviewed evidence does not establish a universal injectable diluent or storage interval.6 8

Form-specific gap

FDA separately assesses free base and acetate. Neither the cell experiment nor a research-vial listing validates a BAC-water recipe or beyond-use date.6 8

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

The source gives a concentration example using a 10 mg vial.

Solvents mentioned: Bacteriostatic water
Reported parameters: 10 mg in 5 mL gives 2 mg/mL; 200 mcg occupies 0.1 mL. · Reported storage: refrigeration after mixing.

The source describes gentle mixing and avoiding vigorous shaking.

Oral

The source describes capsules and sublingual powder.

Form: Source describes a prepared product
Reported parameters: Reported sublingual contact: 2–3 minutes; reported meal interval: 30 minutes. · Reported storage: cool and dry, away from light.

Nasal

The nasal section reports a 1 mg/mL example and calibrated delivery.

Solvents mentioned: Water — type unspecified
Reported parameters: 10 mg in 10 mL gives 1 mg/mL. · The source specifies 250–500 mcg per calibrated spray; pump output must be measured.

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceWhite lyophilized powderReported appearanceClear solution when reconstitutedReported appearanceCertificate of analysis availableReported concernYellow or discolored powderReported concernCloudy solution after mixingReported variationDosing confusion widespread

Vial sizes

10mg8

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.

Injectable

Unverified report22

30 days2–8°C

Full storage notes from Pep-Pedia

Injectable

Refrigerate at 2-8°C, use within 30 days of reconstitution

Oral

Cool, dry place or refrigerate

Nasal

Refrigerate spray bottle, keep upright

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Pen & syringe measurements Scales, capacity & references

Pen & syringe measurements

Device units measure volume. Concentration determines the amount in mg.

Open calculator ↗

V2 peptide pen

1 notch = 0.01 mL

Documented 1-unit V2 models

One dial increment: 1 unit
Cartridge capacity: 3 mL
Maximum setting: 60 units · 0.60 mL

Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.

U-100 syringe

1 unit = 0.01 mL

100 units = 1 mL

10 units: 0.10 mL
30-unit capacity: 0.30 mL
50 / 100-unit capacity: 0.50 / 1 mL

Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.

Other measuring tools

Use the mL scale

mL syringes and calibrated pipettes

0.01 mL: 10 µL
0.10 mL: 100 µL
Amount: mL × mg/mL

Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.

3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.

Device references

AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.

Research findings

Limited human data

Source context

Pep-Pedia's claim that Western doses are 50–100× excessive is unverified here; its 'corrected' doses are not established recommendations.

Source interaction labels and timelines are claims, not combination-safety evidence.

Compound identity & other names

A synthetic tetrapeptide investigated in aging biology. A small older human report concerns melatonin biomarkers; the better-known telomere results are from cell cultures. None establishes longer human life, and epithalamin-extract results must not be relabeled as Epitalon trials.

Other names: Epithalon · Epithalone · AEDG · Ala-Glu-Asp-Gly

No FDA-approved Epitalon product.

How it may work

Proposed telomerase, melatonin, gene-expression and antioxidant effects; oral/nasal absorption and preferential brain delivery remain uncertain.22

Telomerase finding was in cell culture

A 2003 experiment found telomerase activation and telomere elongation in cultured human fetal fibroblasts exposed to Epithalon. It did not test lifespan or clinical outcomes in people.

Later mechanistic work is still preclinical

A 2025 study examined normal and breast-cancer cell lines, reporting changes in telomere biology. Such cellular endpoints cannot demonstrate rejuvenation, cancer protection, or safe human longevity treatment.

Human melatonin report has limited detail

A 2007 publication reports changes in nighttime melatonin in elderly people after pineal peptides, including Epitalon. The checked abstract does not specify the human sample size, allocation, or exact regimen; a biomarker change does not establish better sleep or longevity.

Research areas and evidence gaps

Telomere biology research. Cell studies investigate telomerase and telomere maintenance; these are not human lifespan results.1 2

Whether synthetic Epitalon improves any meaningful human aging outcome.
Human dose-response, long-term safety, and consequences of altered telomere maintenance.
Which historical reports studied Epitalon versus the distinct epithalamin extract.

Community reports Unvalidated

Community protocols discuss sleep and longevity, but human outcome claims often blur Epitalon with epithalamin.7

No verified protocol comparison shows which, if any, benefits people. Self-reported sleep changes are not evidence of longer lifespan.

Search coverage and review status

Additional recent evidence was checked, including Epitalon and telomere maintenance in human cell lines. See individual source summaries for findings and limitations.

Checked: 2026-10-12
Search: Epitalon OR Epithalon 2025 2026
Catalog: Pep-Pedia ↗ · 13 listed references retained

Targeted search, not a systematic or exhaustive review.
Retained bibliography entries marked Bibliography only have not been independently verified.
Distinct URLs may refer to the same publication; component and formulation boundaries remain important.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

22 sources

1Epithalon induces telomerase activity in human somatic cell culturesPreclinical · 2003 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

Cultured human fetal fibroblasts showed telomerase activation and telomere elongation after exposure. No human participant or lifespan outcome was studied.

Telomerase finding was in cell culture

A 2003 experiment found telomerase activation and telomere elongation in cultured human fetal fibroblasts exposed to Epithalon. It did not test lifespan or clinical outcomes in people.

Original source

2Epitalon and telomere maintenance in human cell linesPreclinical · 2025 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

Mechanistic work in normal and breast-cancer cell lines examines telomerase and alternative telomere maintenance. It cannot establish clinical anti-aging benefit or safety.

Later mechanistic work is still preclinical

Additional research · Checked 2026-10-12

Original source

3FDA: compounding safety concernsRegulator · 2026 · fda.govPrimary source checked

AI-PREPARED SUMMARY

FDA identifies inadequate safety information and potential immune-reaction concerns for Epitalon.

Original source

4Pineal peptides and melatonin rhythms in old monkeys and elderly peopleTrial · 2007 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

The abstract describes Epitalon and epithalamin-associated melatonin changes, including elderly participants. Design and dose details are not supplied in the checked abstract; clinical sleep and longevity benefits are not established.

Human melatonin report has limited detail

Original source

5PubChem: Epitalon molecular identityChemical database · 2026 · pubchem.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

Registry entry for Ala-Glu-Asp-Gly, the synthetic tetrapeptide; molecular identity is distinct from pineal extracts.

Original source

6FDA assessment of Epitalon free base and acetateRegulator · 2026 · fda.govPrimary source checked

AI-PREPARED SUMMARY

Reviews limited clinical evidence, absent pharmacokinetic data and unresolved toxicology, including concerns about sustained telomerase activation. It is not an approved label.

Original source

7Pep-Pedia: epitalon community protocol referenceCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

The reference page publishes very different microgram and milligram schedules. This documents inconsistency in community conventions, not a validated dose.

Original source

8Vantage Research Labs Epithalon/Epitalon catalogCatalog · 2026 · vantageresearchlabs.comCatalog checked

AI-PREPARED SUMMARY

The checked catalog identifies a 10 mg research-vial configuration. A catalog amount does not establish a treatment dose or pharmaceutical quality.

Original source

9Neurogenesis Gene Expression Study (2020)Bibliography · 2020 · pmc.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Cultured gingival stem cells showed 1.6–1.8-fold changes in neuronal-differentiation markers; no patient neurological outcome was measured.

Reported population / model
Human stem cells

Reported study details
0.01μg/ml · 7 days · Enhanced differentiation

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

10Ashapkin, V.V., Kutueva, L.I., Kurchashova, S.Y. (2025). Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6), 2691.Bibliography · 2025 · mdpi.comPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The source claims improved vision in 90% of AMD patients at microgram eye doses; sample size and controlled outcomes are not supplied.

Reported population / model
Human (AMD patients)

Reported study details
5μg per eye · 10 days · 90% positive response

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

11Labunets, I.F., Khavinson, V.Kh., Stepanyuk, G.I. (2002). Geroprotective effect of thymalin and epithalamin. Bulletin of Experimental Biology and Medicine, 134(5), 451-453.Epithalamin is a pineal extract, not synthetic Epitalon; its results cannot be assigned to the tetrapeptide.Bibliography · 2002 · pubmed.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Cultured fibroblasts reportedly activated telomerase and extended replication from 34 to at least 44 passages; this is not evidence of longer human life.

Reported population / model
Human cells

Reported study details
0.1μM · 5 days · Extended Hayflick limit

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Epithalamin is a pineal extract, not synthetic Epitalon; its results cannot be assigned to the tetrapeptide.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

12Anisimov, V.N., Khavinson, V.Kh., Morozov, V.G. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193-202.Bibliography · 2003 · pubmed.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: A mouse study is described as showing approximately 25% longer life and fewer chromosome abnormalities with intermittent microgram dosing.

Reported population / model
Mice

Reported study details
1μg per mouse · 5 days/month · 25% lifespan increase

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

13Khavinson, V.Kh., Bondarev, I.E., Butyugov, A.A. (2003). Peptide correction of age-related pineal disturbances in monkeys. Bulletin of Experimental Biology and Medicine, 135(1), 18-21.Bibliography · 2003 · pubmed.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The source attributes melatonin rhythm and sleep changes to synthetic Epitalon in older adults; formulation and study identity require confirmation.

Reported population / model
Human (elderly)

Reported study details
10μg daily · 10 days · Normalized melatonin

Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

14Russian Clinical Trials with Epithalamin Extract (1992-2007)Epithalamin is a pineal extract, not synthetic Epitalon; its results cannot be assigned to the tetrapeptide.Bibliography · 1992 · pubmed.ncbi.nlm.nih.govPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The longevity observations concern Epithalamin extract, not synthetic Epitalon; the source reports lower mortality during long-term follow-up.

Reported population / model
Human

Reported study details
Epithalamin 10mg IM · 15 years follow-up · Reduced mortality

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Listed study

15Kossoy, G., Anisimov, V.N., Ben-Hur, H., Kossoy, N. (2006). Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo, 20(2), 253-257.Bibliography · 2006 · pubmed.ncbi.nlm.nih.govLinked reference · Not independently reviewed

REFERENCE NOTE